Cargando…

Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders

AIMS: This study aimed to compare the performance of Positive and Negative Syndrome Scale (PANSS) symptom severity criteria established by the Remission in Schizophrenia Working Group (RSWG) with criteria based on Clinical Global Impression (CGI) severity score. The 6-month duration criterion was no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinna, Federica, Deriu, Luca, Diana, Enrica, Perra, Valeria, Randaccio, Rachele Pisu, Sanna, Lucia, Tusconi, Massimo, Carpiniello, Bernardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332923/ https://www.ncbi.nlm.nih.gov/pubmed/25699085 http://dx.doi.org/10.1186/s12991-015-0042-6

Ejemplares similares

Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders
por: Pinna, Federica, et al.
Publicado: (2013)

Gender Differences in Remission and Recovery of Schizophrenic and Schizoaffective Patients: Preliminary Results of a Prospective Cohort Study
por: Carpiniello, Bernardo, et al.
Publicado: (2012)

Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy
por: Pinna, Federica, et al.
Publicado: (2015)

Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval
por: Gharabawi, Georges M, et al.
Publicado: (2007)

A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting
por: Hsieh, Ming-Hong, et al.
Publicado: (2010)

Does duration of untreated psychosis predict very long term outcome of schizophrenic disorders? results of a retrospective study
por: Primavera, Diego, et al.
Publicado: (2012)

A structured interview guide for global impressions: increasing reliability and scoring accuracy for CNS trials
por: Targum, Steven D, et al.
Publicado: (2013)

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
por: Carpiniello, Bernardo, et al.
Publicado: (2016)

Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study
por: Primavera, Diego, et al.
Publicado: (2017)

Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances
por: Pinna, Federica, et al.
Publicado: (2014)

Relationship of cognitive function in patients with schizophrenia in remission to disability: a cross-sectional study in an Indian sample
por: Krishnadas, Rajeev, et al.
Publicado: (2007)

Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders
por: Manchia, Mirko, et al.
Publicado: (2022)

Neurophysiological Distinction between Schizophrenia and Schizoaffective Disorder
por: Mathalon, Daniel H., et al.
Publicado: (2010)

Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder
por: Archibald, Luke, et al.
Publicado: (2019)

Alexithymia in eating disorders: therapeutic implications
por: Pinna, Federica, et al.
Publicado: (2014)

Efficacy and tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Andrade, Chittaranjan
Publicado: (2004)

Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Chavda, R.K., et al.
Publicado: (2004)

Measuring Emotional Awareness in Patients With Schizophrenia and Schizoaffective Disorders
por: Maaßen, Eva, et al.
Publicado: (2021)

Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population
por: Mosolov, Sergey N, et al.
Publicado: (2012)

Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder
por: Kim, Sung-Wan, et al.
Publicado: (2015)

The continuing story of schizophrenia and schizoaffective disorder: One condition or two?
por: Hartman, Leah I., et al.
Publicado: (2019)

Religious Coping Strategies for Religious Patients with Schizophrenia and Schizoaffective Disorder
por: Gedevani, E., et al.
Publicado: (2022)

The use of technologies and social media in patients with schizophrenia and schizoaffective disorder
por: Elleuch, O., et al.
Publicado: (2022)

Clinical factors affecting functioning in patients with schizophrenia or schizoaffective disorder
por: Neily, C., et al.
Publicado: (2022)

Psychiatry during the Covid-19 pandemic: a survey on mental health departments in Italy
por: Carpiniello, Bernardo, et al.
Publicado: (2020)

microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder
por: Perkins, Diana O, et al.
Publicado: (2007)

Social function in schizophrenia and schizoaffective disorder: Associations with personality, symptoms and neurocognition
por: Lysaker, Paul H, et al.
Publicado: (2004)

Trauma and Posttraumatic Stress Disorder (PTSD) in Patients with Schizophrenia or Schizoaffective Disorder
por: Lommen, Miriam J. J., et al.
Publicado: (2009)

Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
por: Min, Aran, et al.
Publicado: (2013)

Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder
por: Arion, Dominique, et al.
Publicado: (2015)

Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis
por: Fryar-Williams, Stephanie, et al.
Publicado: (2015)

The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
por: Ko, Young-Hoon, et al.
Publicado: (2014)

Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder
por: Hirjak, Dusan, et al.
Publicado: (2016)

Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder
por: Amann, B. L., et al.
Publicado: (2015)

Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders
por: Tavakoli-Ardakani, Maria, et al.
Publicado: (2018)

Impairment in delay discounting in schizophrenia and schizoaffective disorder but not primary mood disorders
por: Brown, Hannah E., et al.
Publicado: (2018)

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine
por: Kesserwani, Jad, et al.
Publicado: (2019)

Social and Neurocognitive Deficits in Remitted Patients with Schizophrenia, Schizoaffective and Bipolar Disorder
por: Dehelean, Liana, et al.
Publicado: (2021)

Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder
por: Rossom, Rebecca C., et al.
Publicado: (2022)

Testing the hypothesis of subtypes of nonadherence in schizophrenia and schizoaffective disorder: A prospective study
por: Vega, Dulcinea, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m1mbbhvvr6cgqj35dbuugjleic